Cargando…

Glioblastoma Metabolism: Insights and Therapeutic Strategies

Tumor metabolism is emerging as a potential target for cancer therapies. This new approach holds particular promise for the treatment of glioblastoma, a highly lethal brain tumor that is resistant to conventional treatments, for which improving therapeutic strategies is a major challenge. The presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhard, Chloé, Reita, Damien, Martin, Sophie, Entz-Werle, Natacha, Dontenwill, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252397/ https://www.ncbi.nlm.nih.gov/pubmed/37298093 http://dx.doi.org/10.3390/ijms24119137

Ejemplares similares

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin
por: Sani, Saidu, et al.
Publicado: (2022)

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications
por: Lhermitte, Benoit, et al.
Publicado: (2023)

HGG-36. HIF-2: A NEW DRUG TARGET IN PEDIATRIC HIGH-GRADE GLIOMA WITH PROMISING PRECLINICAL RESULTS
por: Fuchs, Quentin, et al.
Publicado: (2020)

HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022)

HGG-34. A DNA DAMAGE REPAIR SIGNATURE IN PRIMARY AND RECURRENT PEDIATRIC HIGH-GRADE GLIOMAS: PROGNOSTIC AND THERAPEUTIC VALUE
por: Entz-Werle, Natacha, et al.
Publicado: (2021)

Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability
por: Pierrevelcin, Marina, et al.
Publicado: (2020)

Hypoxia Inducible Factors’ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches
por: Fuchs, Quentin, et al.
Publicado: (2020)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

TBIO-17. INTEGRATIVE ANALYSES OF BRAFv600e MUTATED GLIOMAS: FROM MOLECULAR BIOLOGY TO RADIOLOGY AND TREATMENTS
por: Lhermitte, Benoit, et al.
Publicado: (2020)

Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity
por: Blandin, Anne-Florence, et al.
Publicado: (2019)

DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
por: Geyer, Lucas, et al.
Publicado: (2023)

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances
por: Geyer, Lucas, et al.
Publicado: (2023)

DIPG-31. HIF-1A AND HIF-2A COMBINATORIAL TARGETING OR HOW TO REVERSE THEIR BALANCED ONCOGENIC IMPACT
por: Fuchs, Quentin, et al.
Publicado: (2023)

A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value
por: Entz-Werlé, Natacha, et al.
Publicado: (2021)

Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas
por: Pinto, Lia, et al.
Publicado: (2021)

LGG-16. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
por: Courant, Marie, et al.
Publicado: (2022)

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
por: Sabo, Amelia-Naomi, et al.
Publicado: (2021)

Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas
por: Nazon, Charlotte, et al.
Publicado: (2022)

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
por: Schaffner, Florence, et al.
Publicado: (2013)

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

DIPG-30. HIF2 OVEREXPRESSION DICTATES AGGRESSIVENESS ADDITIONALLY TO TP53 MUTATIONS IN H3.3K27M PEDIATRIC HIGH-GRADE GLIOMAS THROUGH RAS-MAPK AND WNT/BCATENIN PATHWAYS
por: Fuchs, Quentin, et al.
Publicado: (2023)

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
por: Blandin, Anne-Florence, et al.
Publicado: (2015)

Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets
por: Erices, José Ignacio, et al.
Publicado: (2023)

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells
por: McCartin, Conor, et al.
Publicado: (2022)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
por: Paolillo, Mayra, et al.
Publicado: (2018)

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
por: Haddad, Alexander F, et al.
Publicado: (2021)

Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
por: Zhou, Weihua, et al.
Publicado: (2019)

Current Therapeutic Strategies for Glioblastoma
por: Rossignol, Julien, et al.
Publicado: (2019)

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
por: Nguyen, Aurelia, et al.
Publicado: (2013)

Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma
por: Ahmad, Fahim, et al.
Publicado: (2019)

Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies
por: Yu, Tianzheng, et al.
Publicado: (2023)

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
por: Mercier, Marie-Cécile, et al.
Publicado: (2017)

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity
por: Cai, Xue, et al.
Publicado: (2017)

Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies
por: Yang, Tianrui, et al.
Publicado: (2022)

Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment—An Update
por: Gawel, Agata M., et al.
Publicado: (2022)

Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma
por: Sun, Yanfei, et al.
Publicado: (2023)

Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2021)

Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms
por: Torrisi, Filippo, et al.
Publicado: (2023)

Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting
por: Vieira de Castro, Joana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t76afam7grb8om7gvdn04kdgvv